Showing 1 to 5 of 5 Clinical Trials
CLINICAL TRIAL
    Trial No
    ClinicalTrials.gov ID
Principal Investigator
Coordinator
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
    Krascendo 170
    NCT05789082
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Non Small Cells - Lung Dr. Jennifer Friedmann

Chadi Zakaria
  514-340-8222 poste 28326
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
    SPARTA
    NCT03175224
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Non Small Cells - Lung Dr. Jason Agulnik

Daria Krutauz
  514-340-8222 poste 24301
Liquid biopsy for Non-Small Cell Lung Cancer: comparing plasma cell-free DNA/RNA to tissue NGS to assesses turnaround time, patient distress and cost-effectiveness
    QC-LIQBIOP
    n.d.
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Non Small Cells - Lung Dr. Jason Agulnik

Goulnar Kasymjanova
  514-340-8222 poste 24312
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
    GALAXIES LUNG-201
    NCT05565378
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Non Small Cells - Lung Dr. Khashayar Esfahani

Ashley Ceasar
  514-340-8222 poste 22075
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib
    SAFFRON
    NCT05261399
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Non Small Cells - Lung Dr. Jennifer Friedmann

Aline Mamo
  514-340-8222 poste 5525